Carvalho Jozélio Freire de, Lerner Aaron
Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEN), School of Nutrition from the Federal University of Bahia, Salvador, Bahia, Brazil.
Chaim Sheba Medical Center, The Zabludowicz Research Center for Autoimmune Diseases, Ariel University, Ariel, Israel.
Eur J Rheumatol. 2023 Oct;10(4):163-168. doi: 10.5152/eurjrheum.2023.23064.
Resveratrol is an antioxidant with anti-inflammatory and cell-protective properties. The aim of our article is to review the use of resveratrol in rheumatic diseases. PubMed/Medline, Embase, and Scielo were screened for articles on resveratrol and rheumatic diseases in the period between of January 1966 and March 2023. Five articles were depicted, including 481 patients. The included diseases were osteoarthritis (n=3), rheumatoid arthritis (n=1), and Takayasu arteritis (n=1). The age varied from 32 to 58.2 years, and the female gender ranged from 62% to 74% in the studies. Disease duration ranged from 3.5 ± 3.2 to 9.4 ± 5.8 years. The resveratrol dosage went from 250 mg to 1000 mg/day. All those articles demonstrated improvements in the diverse rheumatic diseases, including pain intensity, function, disease activity (DAS 28), swelling joints, and reduced inflammation markers (erythrocyte sedimentation rate, C-reactive protein, interleukinIL-1, IL-6, and tumor necrosis factor). No side effects were detected in all studies. In conclusion, resveratrol seems to be a safe therapy for various rheumatic diseases, although the evidence is very limited. The improved subjective and objective complaints and laboratory parameters are promising. However, there is a need to reconfirm, reproduce, and investigate the topic in more extensive, well-controlled, double-blind, cross-over studies.
白藜芦醇是一种具有抗炎和细胞保护特性的抗氧化剂。我们这篇文章的目的是综述白藜芦醇在风湿性疾病中的应用。在1966年1月至2023年3月期间，对PubMed/Medline、Embase和Scielo数据库进行检索，查找关于白藜芦醇和风湿性疾病的文章。共筛选出5篇文章，涉及481例患者。纳入的疾病包括骨关节炎（n = 3）、类风湿关节炎（n = 1）和大动脉炎（n = 1）。研究对象年龄在32至58.2岁之间，女性比例在62%至74%之间。病程为3.5±3.2至9.4±5.8年。白藜芦醇剂量为每日250毫克至1000毫克。所有这些文章均表明，白藜芦醇对多种风湿性疾病有改善作用，包括疼痛强度、功能、疾病活动度（DAS 28）、关节肿胀以及炎症标志物（红细胞沉降率、C反应蛋白、白细胞介素IL-1、IL-6和肿瘤坏死因子）降低。所有研究均未检测到副作用。总之，尽管证据非常有限，但白藜芦醇似乎是治疗各种风湿性疾病的一种安全疗法。主观和客观症状以及实验室参数的改善很有前景。然而，有必要在更广泛、严格对照、双盲、交叉研究中重新确认、重现并深入研究该主题。
